Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Apogee Therapeutics Inc APGE

Healthcare Biotechnology
Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indications in the United States. The company develops Zumilokibart (APG777), a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the... see more

Current News (NDAQ:APGE)

Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $403 Million

GlobeNewswire March 26, 2026

Apogee Therapeutics, Inc. Announces Pricing of $350 Million Underwritten Public Offering

GlobeNewswire March 24, 2026

Apogee Therapeutics, Inc. Announces Proposed $300 Million Underwritten Public Offering

GlobeNewswire March 23, 2026

Apogee Therapeutics Announces Positive Phase 2 Part A 52-Week Data of Zumilokibart (APG777), Demonstrating Maintenance and Deepening of Responses with Every 3- and 6-Month Dosing in Moderate-to-Severe Atopic Dermatitis

GlobeNewswire March 23, 2026

Apogee Therapeutics to Host Conference Call to Report Part A 52-Week Data from the Phase 2 APEX Trial of Zumilokibart (APG777) in Patients with Moderate-to-Severe Atopic Dermatitis on March 23, 2026

GlobeNewswire March 22, 2026

Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2025 Financial Results

GlobeNewswire March 2, 2026

Apogee Therapeutics to Participate in Upcoming March Conferences

GlobeNewswire February 24, 2026

Apogee Therapeutics to Participate at the Guggenheim Emerging Outlook: Biotech Summit 2026

GlobeNewswire February 5, 2026

Apogee Therapeutics Announces Positive Interim Results from Phase 1b Trial of Zumilokibart (APG777), its Potentially Best-in-Class Anti-IL-13 Antibody, in Patients with Mild-to-Moderate Asthma and Highlights 2026 Anticipated Milestones and Outlook

GlobeNewswire January 6, 2026
View More News ››

Opinion & Analysis (NDAQ:APGE)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:APGE)

Reshaping the Standard of Care in Inflammatory and Immunolog

Looks like APGE is making some serious moves in the inflammatory disease space. Their APG777 with a 75-day half-life is pretty impressive...
MikeTester - January 24, 2025
View more Bullboard ››

Mirasol Resources Ltd.

Mirasol Resources Ltd.

Mirasol Resources Ltd. engages in the acquisition and exploration of mineral properties in Chile and Argentina. The company ...
View More »

Podcasts